Number of macula optical coherence tomography scans needed to detect glaucoma progression
- PMID: 39663002
- PMCID: PMC12124970
- DOI: 10.1136/bjo-2023-324916
Number of macula optical coherence tomography scans needed to detect glaucoma progression
Abstract
Background: To evaluate the impact of testing frequency on the time required to detect statistically significant glaucoma progression for ganglion cell complex (GCC) with optical coherence tomography (OCT).
Materials and methods: From multicentre glaucoma registries, 332 eyes of 201 glaucoma patients were enrolled over an average of 4.4 years. Patients with 4 or more OCT tests were selected to calculate the longitudinal rates of GCC thickness change over time by linear regression. A computer simulation was then used to generate real-world GCC data and assess the time required to detect progression at different loss rates and testing frequencies based on variability estimates. Time and accuracy to detect worsening of progression were calculated.
Results: As testing frequency increased, the time required to detect a statistically significant negative GCC slope decreased, but not proportionally. All eyes with a GCC loss of -1 µm/year progressed after 3.8, 2.6 and 2.2 years on average when testing was conducted one, two and three times per year, respectively. For eyes with a GCC loss of -1.5 µm/year, progression was identified after 3.3, 2.2, and 1.8 years on average, respectively.
Conclusion: Increasing the frequency of macular OCT testing to three times per year more sensitively detects progression compared with two times per year. However, two times per year testing may be sufficient in clinical settings to detect progression and also to reduce the healthcare burden.
Trial registration numbers: NCT00221897, NCT00221923.
Keywords: Glaucoma; Macula.
© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: GM: None; SM: None; KL: None; NB: None; EW: None; TN: None; KD: None; GG: None; JHW: None; JML: C: Allergan, Genentech, Thea, Bausch & Lomb; F: Novartis, Research to Prevent Blindness; MF: F: National Eye Institute, EyeSight Foundation of Alabama, Research to Prevent Blindness, Heidelberg Engineering GmbH, Topcon and Wolfram Research; CAG: F: National Eye Institute, Heidelberg Engineering and Topcon, EyeSight Foundation of Alabama, Research to Prevent Blindness, Heidelberg Engineering GmbH, C: iridex; LMZ: C: Abbvie Inc. Topcon F: National Eye Institute, Carl Zeiss Meditec Inc., Heidelberg Engineering GmbH, Optovue Inc., Topcon Medical Systems Inc., P: Carl Zeiss Meditec, AISight Health; C: Abbvie, Aerie Alcon, Amydis, Balance, Iantrek, Implandata, Spinogenix, Topcon Medical, F: Topcon Medical, Centervue, Vasoptic, Visionix, P: Toromedes, Carl Zeiss Meditec.
References
-
- Nguyen AT, Greenfield DS, Bhakta AS, Lee J, Feuer WJ. Detecting Glaucoma Progression Using Guided Progression Analysis with OCT and Visual Field Assessment in Eyes Classified by International Classification of Disease Severity Codes. Ophthalmol Glaucoma 2019;2(1):36–46 doi: 10.1016/j.ogla.2018.11.004[published Online First: Epub Date]|. - DOI - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials